ADTX
Aditxt Inc (ADTX)
Healthcare • NASDAQ • $0.12+1.89%
- Symbol
- ADTX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.12
- Daily Change
- +1.89%
- Market Cap
- $107450
- Trailing P/E
- N/A
- Forward P/E
- -0.01
- 52W High
- $1,979.76
- 52W Low
- $0.10
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.75
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantif…
Company websiteResearch ADTX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.